A Multinational, Randomized, Double-Blind Study of Aflibercept Versus Placebo With Irinotecan/ 5-FU Combination (FOLFIRI) in Patients With Metastatic Colorectal Cancer (MCRC) After Failure of an Oxaliplatin Based Regimen

Trial Profile

A Multinational, Randomized, Double-Blind Study of Aflibercept Versus Placebo With Irinotecan/ 5-FU Combination (FOLFIRI) in Patients With Metastatic Colorectal Cancer (MCRC) After Failure of an Oxaliplatin Based Regimen

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Oct 2016

At a glance

  • Drugs Aflibercept (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms AFLAME
  • Sponsors Sanofi
  • Most Recent Events

    • 25 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 09 Jul 2015 Planned End Date changed from 1 Oct 2015 to 1 Jul 2015 as per ClinicalTrials.gov record.
    • 14 Oct 2014 Status changed from recruiting to active, no longer recruiting, as reported by the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top